CG Oncology (CGON) Other Non Operating Income (2023 - 2026)
CG Oncology's (CGON) quarterly Other Non Operating Income came in at -$101000.0 in Q1 2026, down 2120.0% YoY from $5000.0 in Q1 2025, and down 90.57% on a QoQ basis from -$53000.0 in Q4 2025.
CG Oncology (CGON) Other Non Operating Income (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Other Non Operating Income data on file, last reported at -$101000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 2120.0% year-over-year to -$101000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$258000.0 (down 1617.65% YoY) and the FY2025 annual result came in at -$152000.0, down 5166.67% from the prior year.
- Other Non Operating Income declined to -$101000.0 in Q1 2026, from -$53000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $8000.0 in Q1 2023 to a low of -$101000.0 in Q1 2026.
- A 4-year average of -$24000.0 and a median of -$4000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income jumped 250.0% — and 2025, when it plunged 4900.0%.
- Tracing CGON's Other Non Operating Income over 4 years: stood at -$4000.0 in 2023, then jumped by 250.0% to $6000.0 in 2024, then sank by 983.33% to -$53000.0 in 2025, then slumped by 90.57% to -$101000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$101000.0 (Q1 2026), -$53000.0 (Q4 2025), and -$100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16,000.00 |
| Mar 31, 2026 | -101,000.00 |
| Dec 31, 2025 | -53,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | -9,000.00 |
| Dec 31, 2023 | -4,000.00 |
| Sep 30, 2023 | -8,000.00 |
| Jun 30, 2023 | -58,000.00 |
| Mar 31, 2023 | 8,000.00 |